DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes
Atish Kizhakeyil, Nurmahirah Binte Mohammed Zaini, Zhi Sheng Poh, Brandon Han Siang Wong, Xinpeng Loh, Aik Seng Ng, Zun Siong Low, Praseetha Prasannan, Chun Gong, Michelle Tan, Chandramouli Nagarajan, Dachuan Huang, Pang Wan Lu, Jing Quan Lim, Sharon Barrans, Choon Kiat Ong, Soon Thye Lim, Wee Joo Chng, George Follows, Daniel J. Hodson, Ming‐Qing Du, Yeow Tee Goh, Suat Hoon Tan, Nicholas F. Grigoropoulos, Navin Kumar Verma
Abstract
Non-Hodgkin a diverse group of malignancies, encompassing the common difuse large B-cell lymphoma (DLBCL) to the rarer T-cell lymphomas. Chemoresistance is a major barrier to treatment and the mechanisms through which it occurs are incompletely understood [1]. Although eforts are made to target frequently dysregulated pathways in NHL subtypes, these diseases still evolve into aggressive forms resistant even to newer therapies [2].